Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Oxford Immunotec Global stock

Learn how to easily invest in Oxford Immunotec Global stock.

Oxford Immunotec Global is a diagnostics & research business based in the US. Oxford Immunotec Global shares (OXFD) are listed on the NASDAQ and all prices are listed in US Dollars. Oxford Immunotec Global employs 273 staff and has a trailing 12-month revenue of around $57.3 million.

How to buy Oxford Immunotec Global stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – OXFD. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Oxford Immunotec Global stock price (NASDAQ: OXFD)

Use our graph to track the performance of OXFD stocks over time.

Oxford Immunotec Global shares at a glance

Information last updated 2021-05-02.
52-week range$0.00 - $0.00
50-day moving average $21.94
200-day moving average $16.48
Wall St. target price$22.50
PE ratio 11.746
Dividend yield N/A (0%)
Earnings per share (TTM) $5.18

Buy Oxford Immunotec Global stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Oxford Immunotec Global stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Oxford Immunotec Global stock undervalued or overvalued?

Valuing Oxford Immunotec Global stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Oxford Immunotec Global's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Oxford Immunotec Global's P/E ratio

Oxford Immunotec Global's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Oxford Immunotec Global shares trade at around 12x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Oxford Immunotec Global financials

Revenue TTM $57.3 million
Gross profit TTM $54.4 million
Return on assets TTM -4.99%
Return on equity TTM -8.19%
Profit margin -30.51%
Book value $7.37
Market capitalisation $562.5 million

TTM: trailing 12 months

Oxford Immunotec Global share dividends

We're not expecting Oxford Immunotec Global to pay a dividend over the next 12 months.

Oxford Immunotec Global share price volatility

Over the last 12 months, Oxford Immunotec Global's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

OXFD.US volatility(beta: 1.38)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oxford Immunotec Global's is 1.3781. This would suggest that Oxford Immunotec Global's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Oxford Immunotec Global overview

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT. TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT. CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions.

Frequently asked questions

What percentage of Oxford Immunotec Global is owned by insiders or institutions?
Currently 1.894% of Oxford Immunotec Global shares are held by insiders and 95.723% by institutions.
How many people work for Oxford Immunotec Global?
Latest data suggests 273 work at Oxford Immunotec Global.
When does the fiscal year end for Oxford Immunotec Global?
Oxford Immunotec Global's fiscal year ends in December.
Where is Oxford Immunotec Global based?
Oxford Immunotec Global's address is: 143 Park Drive, Abingdon, United Kingdom, OX14 4SE
What is Oxford Immunotec Global's ISIN number?
Oxford Immunotec Global's international securities identification number is: GB00BGFBB958
What is Oxford Immunotec Global's CUSIP number?
Oxford Immunotec Global's Committee on Uniform Securities Identification Procedures number is: G6855A103

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site